Home »
A cocktail of synthetic antibodies reduces deaths among severe COVID patients who are unable to mount a strong immune response, results from a major clinical trial showed Wednesday. The therapy, developed by the US biotech firm Regeneron and given to former US President Donald Trump during his brush with the coronavirus, had previously only been used to treat patients in […]
Read more
Treatment options for a deadly liver cancer, fibrolamellar carcinoma, are severely lacking. Drugs that work on other liver cancers are not effective, and although progress has been made in identifying the specific genes involved in driving the growth of fibrolamellar tumors, these findings have yet to translate into any treatment. For now, surgery is the only option for those affected—mostly […]
Read more
FDA approves first drug to treat Alzheimer’s patients since 2003 despite controversy over mixed clinical trial results On Monday, the FDA approved aducanumab, which was developed by Biogen Inc, to treat Alzheimer’s disease The drug removes amyloid beta proteins from the brain and could slow down patients’ cognitive decline Aducanumab is not only the first drug of its kind but also […]
Read more
By studying guppies, scientists at the University of Toronto and Florida State University found that behaviors affected by methylphenidate hydrochloride (MPH) – the active ingredient in stimulants such as Ritalin and Concerta used to treat ADHD—can be passed along to several generations of descendants. “We exposed male and female Trinidadian guppies to a low, steady dose of MPH and saw […]
Read more
A study published today in Nature Communications shows that the drug rucaparib has been effective in treating certain types of ovarian cancers if used early in treatment, after a diagnosis, and before the cancer cells build up a resistance to chemotherapy. Rucaparib is in a relatively new class of drugs—Poly(ADP-ribose) polymerase or PARP inhibitors—which have been approved for therapy in ovarian cancers. […]
Read more
A research team from the Institut de Neurociències at the Universitat Autònoma de Barcelona (INc-UAB) has showed that inhibition of the Tac2 neuronal circuit, involved in the formation of the memory of fear, has opposite effects according to sex on the ability to remember aversive events in mice, reducing it in male mice and increasing it in female mice. It […]
Read more
Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harboring this mutation, according to results from a study with the KRASG12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021. “As we strive to identify the oncogenic driver in more and more of our […]
Read more
New study finds the skyrocketing cost of drugs in U.S. used to treat hookworm and other soil-transmitted parasites increases patient costs, suggests decreased quality of care A new study finds that the increasingly high prices in the United States of the drugs used to treat three soil-transmitted helminth infections—hookworm, roundworm (ascariasis), and whipworm (trichuriasis)—is not only the major driver for […]
Read more
In a study published online February 25, 2021 in The New England Journal of Medicine, a repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Results of the Phase III clinical trial, conducted by an international team led by senior author Atul Malhotra, MD, research chief of pulmonary, critical care and […]
Read more
A potentially effective treatment for diabetic retinopathy, a disease that swells and scars the retina, has been developed by an Université de Montréal scientist and investigator at Maisonneuve-Rosemont Hospital Research Centre (MRH-RC). Working with research scientist Pam Tsuruda of the San Francisco-based company UNITY Biotechnology, Przemyslaw (Mike) Sapieha published the results of the research project on mice Friday in the […]
Read more